Bone marrow recuperation by AM3 in breast cancer patients submitted to aggressive adjuvant treatment. A preliminary report.
The results of a prospective randomized study of 46 patients with breast carcinoma are presented. Twenty six patients were treated with AM3 (biological response modifier) associated with adjuvant radiotherapy and chemotherapy. Bone marrow hypoplasia was observed in 26.9% of the patients treated with AM3 compared with a 65% incidence in the control group (P less than 0.05). All patients showed leukopenia in peripheral blood count; however, the nadir of leukocytes was 4,000 leu/mm3 in the test group, compared with 1,900 leu/mm3 in the control group. None of the patients in the AM3 group showed thrombocytopenia, whereas 55% in the control group did. In none of the AM-3-treated cases was it necessary to modify the therapeutic schedule of adjuvant treatment.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects*; D001943:Breast Neoplasms / Q000628:therapy*; D002130:Calcium Phosphates / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006020:Glycopeptides / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents; D002130:Calcium Phosphates; D006020:Glycopeptides; C038773:Immunoferon